approval
saveRYBREVANT FASPRO (AMIVANTAMAB AND HYALURONIDASE-LPUJ) — FDA approval
community read0 votes
Sponsor: JANSSEN BIOTECH. Form: VIAL. Route: SINGLE-USE
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 1
same company · ±60 days · 6
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalFeb 12, 2026
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalJan 27, 2026
- approvalteclistamab: TECVAYLI (TECLISTAMAB-CQYV) — FDA approvalMar 5, 2026
- approvaltalquetamab: TALVEY (TALQUETAMAB-TGVS) — FDA approvalMar 5, 2026
- approvalapalutamide: ERLEADA (APALUTAMIDE) — FDA approvalMar 5, 2026
- approvalicotrokinra hydrochloride: ICOTYDE (ICOTROKINRA HYDROCHLORIDE) — FDA approvalMar 17, 2026
comments(0)
5-min edit window · permanent after that